Martin Heidecker
Managing Director @ Boehringer Ingelheim Venture Fund
Martin Heidecker is a Series A investor at Boehringer Ingelheim Venture Fund focused on Biotechnology and Health Care. Martin Heidecker - Managing Director @ Boehringer Ingelheim Venture Fund
- Total investments:
- 10
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Martin Heidecker invests in
BiotechnologyHealth CareMedicalTherapeuticsPharmaceutical
Stages Martin Heidecker invests in
Series ASeries CSeedSeries BSeries E
Countries Martin Heidecker invests in
United StatesSwitzerland
Investment Focus
Industry
- Biotechnology 8 (80%)
- Health Care 6 (60%)
- Medical 5 (50%)
- Therapeutics 4 (40%)
- Pharmaceutical 4 (40%)
Stage
- Series A 4 (40%)
- Series C 2 (20%)
- Seed 1 (10%)
- Series B 1 (10%)
- Series E 1 (10%)
Country
- United States 8 (80%)
- Switzerland 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vedanta Biosciences
|
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $40M / Venture - Series Unknown / Aug 06, 2026 | |
|
Vedanta Biosciences
|
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M / Series E / Apr 25, 2023 | |
BioVersys
|
Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major globalhealth issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective. | $9M / Series C / Jan 05, 2023 | |
Venatorx Pharmaceuticals
|
Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania. | $34M / Series C / Apr 04, 2022 | |
Adaptive Phage Therapeutics
|
Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistantbacteria. | $20M / Series B / Apr 04, 2022 | |
Libra Therapeutics
|
Libra Therapeutics is a biotechnology company focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases. | $29M / Series A / Sep 23, 2020 | |
Rgenta Therapeutics
|
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its leadprograms and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.It was founded in 2018 and is headquartered in Cambridge, Massachusetts. | $20M / Seed / Apr 02, 2020 | |
Sentien Biotechnologies
|
Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extendtherapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States. | $12M / Series A / Apr 04, 2017 | |
Sentieon
|
Sentieon develops and commercializes cloud-based bio-informatics solutions for the life sciences and clinical market. They develop and supply a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency, fast turnaround time, accuracy, and consistency. Some of the released products include SentieonDNAseq, a germline DNA pipeline; and Sentieon TNseq, for tumor-normal somatic variant detection. The company’s tools are scalable, deployable, upgradable, and software-only solutions. The Sentieon tools achieve their efficiency and consistency through optimized computing algorithm design and enterprise-strength software implementation.The company was founded by Jun Ye in 2014 and is headquartered in Mountain View, California. | $3.8M / Series A / Apr 04, 2014 | |
ArmaGen Technologies
|
ArmaGen is a developer of therapies designed to address neurological complications. The company's pipeline of innovative therapies penetrate the blood-brain barrier to treat neurological complications of many diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's, enabling patients suffering fromneurodegenerative disorders to get improved treatment. | $17M / Series A / Nov 29, 2012 |
Co-Investors
Mass Medical Angels
2 deals together
Abingworth
1 deal together
Atlantic Neptune
1 deal together
AXA Investment Managers
1 deal together
Bill & Melinda Gates Foundation
1 deal together
BioInnovation
1 deal together
About Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.
Boehringer Ingelheim Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Debbie Lin
Executive Director
|
|||
Knut Elbers
Project Manager
|
|||
|
Martin Heidecker
Managing Director
|
|||
Oliver Reuss
Executive Director and Investment Manager
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Martin Heidecker invest in?
Martin Heidecker invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Martin Heidecker last invest?
The most recent investment recorded for Martin Heidecker closed in Aug 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
